Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Recurrence 3Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Prolymphocytic, T-Cell 2Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Recurrence × duvelisib × Clear all
NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT06522737 2026-04-06

TERZO

SecuraBio

Phase 3 Recruiting
124 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT06810778 2025-07-15

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡